Literature DB >> 29071382

Hydroxyethyl starch 130/0.4 versus crystalloid co-loading during general anesthesia induction: a randomized controlled trial.

Takashi Juri1, Koichi Suehiro2, Shigemune Kuwata1, Sayaka Tsujimoto1, Akira Mukai1, Katsuaki Tanaka1, Tokuhiro Yamada1, Takashi Mori1, Kiyonobu Nishikawa1.   

Abstract

PURPOSE: Hypotension and decreased cardiac output (CO) are common adverse effects during anesthesia induction depending on the patient's pre-anesthetic cardiac condition. The aim of this study was to assess the ability of hydroxyethyl starch (HES) 130/0.4 to prevent hypotension and decreased CO during the induction of general anesthesia.
METHODS: Ninety patients undergoing laparoscopic surgery were randomly divided into a HES group and a crystalloid group. Following the insertion of an intravenous line, fluid was administered to each patient at a rate of 25 ml/min using either crystalloid or HES 130/0.4. Five minutes after the initiation of fluid loading, anesthesia was induced using propofol (1.5 mg/kg), rocuronium (0.9 mg/kg), and remifentanil (0.3 mcg/kg/min). Tracheal intubation was performed 5 min after the induction of anesthesia. Following tracheal intubation, general anesthesia was maintained using remifentanil and sevoflurane. Non-invasive blood pressure (BP) level was measured at 1-min intervals and CO was measured continuously using electrical cardiometry from the start of fluid loading until 5 min after tracheal intubation.
RESULTS: The number of patients with hypotension (systolic BP < 90 mmHg or 80% of baseline) was significantly lower in the HES group (p < 0.001) than in the crystalloid group. Patients in the HES group showed smaller CO decreases than did patients in the crystalloid group (p < 0.001). The Kaplan-Meier method showed a lower incidence and significantly slower onset of hypotension in the HES group (p = 0.009). Multivariate logistic regression models indicated that the use of HES is an independent factor for the prevention of both hypotension and decreased CO (below 85% of baseline; p < 0.005 for both).
CONCLUSIONS: Co-loading using HES 130/0.4 prevented hypotension and decreased CO during general anesthesia induction.

Entities:  

Keywords:  Cardiac output; Hydroxyethyl starch 130/0.4; Hypotension

Mesh:

Substances:

Year:  2017        PMID: 29071382     DOI: 10.1007/s00540-017-2416-1

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  28 in total

Review 1.  Accuracy and precision of minimally-invasive cardiac output monitoring in children: a systematic review and meta-analysis.

Authors:  Koichi Suehiro; Alexandre Joosten; Linda Suk-Ling Murphy; Olivier Desebbe; Brenton Alexander; Sang-Hyun Kim; Maxime Cannesson
Journal:  J Clin Monit Comput       Date:  2015-08-29       Impact factor: 2.502

2.  Intraoperative hypotension and 1-year mortality after noncardiac surgery.

Authors:  Jilles B Bijker; Wilton A van Klei; Yvonne Vergouwe; Douglas J Eleveld; Leo van Wolfswinkel; Karel G M Moons; Cor J Kalkman
Journal:  Anesthesiology       Date:  2009-12       Impact factor: 7.892

3.  New 6% hydroxyethyl starch 130/0.4 does not increase blood loss during major abdominal surgery - a randomized, controlled trial.

Authors:  Ming-Hui Hung; Conghua Zou; Feng-Sheng Lin; Chen-Jung Lin; Kuang-Cheng Chan; Yanqing Chen
Journal:  J Formos Med Assoc       Date:  2012-09-01       Impact factor: 3.282

4.  Colloid preload versus coload for spinal anesthesia for cesarean delivery: the effects on maternal cardiac output.

Authors:  Wendy H L Teoh; Alex T H Sia
Journal:  Anesth Analg       Date:  2009-05       Impact factor: 5.108

5.  Changes in intravascular volume during acute normovolemic hemodilution and intraoperative retransfusion in patients with radical hysterectomy.

Authors:  M Rehm; V Orth; U Kreimeier; M Thiel; M Haller; H Brechtelsbauer; U Finsterer
Journal:  Anesthesiology       Date:  2000-03       Impact factor: 7.892

6.  Preload or coload for spinal anesthesia for elective Cesarean delivery: a meta-analysis.

Authors:  Arnab Banerjee; Renato M Stocche; Pamela Angle; Stephen H Halpern
Journal:  Can J Anaesth       Date:  2009-10-27       Impact factor: 5.063

7.  Balanced crystalloid compared with balanced colloid solution using a goal-directed haemodynamic algorithm.

Authors:  A Feldheiser; V Pavlova; T Bonomo; A Jones; C Fotopoulou; J Sehouli; K-D Wernecke; C Spies
Journal:  Br J Anaesth       Date:  2012-10-30       Impact factor: 9.166

8.  Association between Intraoperative Hypotension and Myocardial Injury after Vascular Surgery.

Authors:  Judith A R van Waes; Wilton A van Klei; Duminda N Wijeysundera; Leo van Wolfswinkel; Thomas F Lindsay; W Scott Beattie
Journal:  Anesthesiology       Date:  2016-01       Impact factor: 7.892

Review 9.  Optimal perioperative management of arterial blood pressure.

Authors:  Laurent Lonjaret; Olivier Lairez; Vincent Minville; Thomas Geeraerts
Journal:  Integr Blood Press Control       Date:  2014-09-12

Review 10.  Incidence of postoperative death and acute kidney injury associated with i.v. 6% hydroxyethyl starch use: systematic review and meta-analysis.

Authors:  M A Gillies; M Habicher; S Jhanji; M Sander; M Mythen; M Hamilton; R M Pearse
Journal:  Br J Anaesth       Date:  2013-09-17       Impact factor: 9.166

View more
  2 in total

1.  Effect of remifentanil infusion on the hemodynamic response during induction of anesthesia in hypertensive and normotensive patients: a prospective observational study.

Authors:  Soo Kyung Lee; Mi Ae Jeong; Jeong Min Sung; Hyo Jin Yeon; Ji Hee Chang; Hyunyoung Lim
Journal:  J Int Med Res       Date:  2019-11-04       Impact factor: 1.671

2.  Mechanisms contributing to hypotension after anesthetic induction with sufentanil, propofol, and rocuronium: a prospective observational study.

Authors:  Bernd Saugel; Elisa-Johanna Bebert; Luisa Briesenick; Phillip Hoppe; Gillis Greiwe; Dongsheng Yang; Chao Ma; Edward J Mascha; Daniel I Sessler; Dorothea E Rogge
Journal:  J Clin Monit Comput       Date:  2021-02-01       Impact factor: 1.977

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.